Limits...
Decrease in irisin in patients with chronic kidney disease.

Wen MS, Wang CY, Lin SL, Hung KC - PLoS ONE (2013)

Bottom Line: The decrease in irisin levels was inversely correlated with the levels of blood urea nitrogen and creatinine.Further association analysis revealed that irisin level is independently associated with high-density lipoprotein cholesterol level.Our results suggest that chronic kidney disease patients have lower than normal irisin levels at rest.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan. ocean.laboratory@me.com

ABSTRACT
Patients with chronic kidney disease have abnormal energy expenditure and metabolism. The mechanisms underlying altered energy expenditure in uremia are unknown and remain to be elucidated. Irisin is a peroxisome proliferator-activated receptor Ī³ coactivator 1-Ī±-dependent myokine, and it increases energy expenditure in the absence of changes in food intake or activity. We hypothesize that chronic kidney disease patients have altered irisin levels. We measured resting irisin levels in 38 patients with stage 5 chronic kidney disease and in 19 age- and sex-matched normal subjects. Plasma irisin levels were significantly decreased in chronic kidney disease patients (58.59%; 95% CI 47.9%-69.2%, p<0.0001). The decrease in irisin levels was inversely correlated with the levels of blood urea nitrogen and creatinine. Further association analysis revealed that irisin level is independently associated with high-density lipoprotein cholesterol level. Our results suggest that chronic kidney disease patients have lower than normal irisin levels at rest. Furthermore, irisin may play a major role in affecting high-density lipoprotein cholesterol levels and abnormal energy expenditure in chronic kidney disease patients.

Show MeSH

Related in: MedlinePlus

Irisin in healthy subjects and in patients with chronic kidney disease.A, Irisin expression measured by western blot analysis in normal control subjects (N) (nā€Š=ā€Š19) and in chronic kidney disease (CKD) patients (nā€Š=ā€Š38). Representative blots were chosen from 2 healthy subjects and 2 CKD patients. B, Irisin expression measured by ELISA in normal control subjects and CKD patients.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3646802&req=5

pone-0064025-g001: Irisin in healthy subjects and in patients with chronic kidney disease.A, Irisin expression measured by western blot analysis in normal control subjects (N) (nā€Š=ā€Š19) and in chronic kidney disease (CKD) patients (nā€Š=ā€Š38). Representative blots were chosen from 2 healthy subjects and 2 CKD patients. B, Irisin expression measured by ELISA in normal control subjects and CKD patients.

Mentions: After albumin/IgG depletion and deglycosylation, we were able to detect irisin with western blotting, according to the protocol described previously (Fig. 1A).[13] An immunoreactive band at 22 kDa was obtained for serum irisin and positive control protein lysates. Additionally, variations in the plasma irisin levels were observed among the 19 normal subjects after normalization with the control protein lysate (1.058Ā±0.091; 95% confidence interval [CI] 0.8677ā€“1.248). The minimum irisin level was 0.54 and the maximum level was 1.954, although this study excluded subjects who had participated in regular and strenuous exercise within 1 month of the study. Compared with normal subjects, the irisin levels in CKD patients were lower (0.6199Ā±0.056; 95% CI 0.5072ā€“0.7326) and significantly decreased (58.59%; 95% CI 47.9%ā€“69.2%, p<0.0001) (Fig. 1A).


Decrease in irisin in patients with chronic kidney disease.

Wen MS, Wang CY, Lin SL, Hung KC - PLoS ONE (2013)

Irisin in healthy subjects and in patients with chronic kidney disease.A, Irisin expression measured by western blot analysis in normal control subjects (N) (nā€Š=ā€Š19) and in chronic kidney disease (CKD) patients (nā€Š=ā€Š38). Representative blots were chosen from 2 healthy subjects and 2 CKD patients. B, Irisin expression measured by ELISA in normal control subjects and CKD patients.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3646802&req=5

pone-0064025-g001: Irisin in healthy subjects and in patients with chronic kidney disease.A, Irisin expression measured by western blot analysis in normal control subjects (N) (nā€Š=ā€Š19) and in chronic kidney disease (CKD) patients (nā€Š=ā€Š38). Representative blots were chosen from 2 healthy subjects and 2 CKD patients. B, Irisin expression measured by ELISA in normal control subjects and CKD patients.
Mentions: After albumin/IgG depletion and deglycosylation, we were able to detect irisin with western blotting, according to the protocol described previously (Fig. 1A).[13] An immunoreactive band at 22 kDa was obtained for serum irisin and positive control protein lysates. Additionally, variations in the plasma irisin levels were observed among the 19 normal subjects after normalization with the control protein lysate (1.058Ā±0.091; 95% confidence interval [CI] 0.8677ā€“1.248). The minimum irisin level was 0.54 and the maximum level was 1.954, although this study excluded subjects who had participated in regular and strenuous exercise within 1 month of the study. Compared with normal subjects, the irisin levels in CKD patients were lower (0.6199Ā±0.056; 95% CI 0.5072ā€“0.7326) and significantly decreased (58.59%; 95% CI 47.9%ā€“69.2%, p<0.0001) (Fig. 1A).

Bottom Line: The decrease in irisin levels was inversely correlated with the levels of blood urea nitrogen and creatinine.Further association analysis revealed that irisin level is independently associated with high-density lipoprotein cholesterol level.Our results suggest that chronic kidney disease patients have lower than normal irisin levels at rest.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan. ocean.laboratory@me.com

ABSTRACT
Patients with chronic kidney disease have abnormal energy expenditure and metabolism. The mechanisms underlying altered energy expenditure in uremia are unknown and remain to be elucidated. Irisin is a peroxisome proliferator-activated receptor Ī³ coactivator 1-Ī±-dependent myokine, and it increases energy expenditure in the absence of changes in food intake or activity. We hypothesize that chronic kidney disease patients have altered irisin levels. We measured resting irisin levels in 38 patients with stage 5 chronic kidney disease and in 19 age- and sex-matched normal subjects. Plasma irisin levels were significantly decreased in chronic kidney disease patients (58.59%; 95% CI 47.9%-69.2%, p<0.0001). The decrease in irisin levels was inversely correlated with the levels of blood urea nitrogen and creatinine. Further association analysis revealed that irisin level is independently associated with high-density lipoprotein cholesterol level. Our results suggest that chronic kidney disease patients have lower than normal irisin levels at rest. Furthermore, irisin may play a major role in affecting high-density lipoprotein cholesterol levels and abnormal energy expenditure in chronic kidney disease patients.

Show MeSH
Related in: MedlinePlus